Latest / Community Health Media
Dr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer
Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy.
From DESTINY-Breast 11’s practice-changing neoadjuvant results to DESTINY-Breast 05 in the adjuvant setting — and now DESTINY-Breast 09 rewriting the metastatic playbook — the data are clear: trastuzumab deruxtecan (T-DXd) is transforming treatment across disease stages.
The discussion moves beyond HER2 + disease into HER2-low and ultra-low, touching on how new definitions, ADC sequencing, and precision testing could expand eligibility to the majority of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.